Roles of rifampicin in drug-drug interactions: Underlying molecular mechanisms involving the nuclear pregnane X receptor

被引:223
作者
Chen J. [1 ]
Raymond K. [1 ]
机构
[1] School of Pharmacy, Faculty of Science, Technology and Engineering, La Trobe University, Bendigo
关键词
Digoxin; Rifampicin; Rosiglitazone; Felodipine; Rifabutin;
D O I
10.1186/1476-0711-5-3
中图分类号
学科分类号
摘要
Rifampicin, an important drug in the treatment of tuberculosis, is used extensively despite its broad effects on drug-drug interactions, creating serious problems. The clinical importance of such interactions includes autoinduction leading to suboptimal or failed treatment. The concomitantly administered effects of rifampicin on other drugs can result in their altered metabolism or transportation that are metabolised by cytochromes P450 or transported by p-glycoprotein in the gastrointestinal tract and liver. This review paper summarises recent findings with emphases on the molecular mechanisms used to explain these broad drug-drug interactions. In general, rifampicin can act on a pattern: rifampicin activates the nuclear pregnane X receptor that in turn affects cytochromes P450, glucuronosyltransferases and p-glycoprotein activities. This pattern of action may explain many of the rifampicin inducing drug-drug interactions. However, effects through other mechanisms have also been reported and these make any explanation of such drug-drug interactions more complex. © 2006 Chen and Raymond; licensee BioMed Central Ltd.
引用
收藏
页数:11
相关论文
共 133 条
[1]
Dlodlo R.A., Fujiwara P.I., Enarson D.A., Should tuberculosis treatment and control be addressed differently in HIV-infected and -uninfected individuals?, Eur Respir J, 25, pp. 751-757, (2005)
[2]
Nies A.S., Principles of the therapeutics, Goodman & Gilman's The Pharmacological Basis of Therapeutics, pp. 45-66, (2001)
[3]
le Grand A., Hogerzeil H.V., Haaijer-Ruskamp F.M., Intervention research in rational use of drugs: A review, Health Policy Plan, 14, pp. 89-102, (1999)
[4]
Davies P.D., Yew W.W., Recent developments in the treatment of tuberculosis, Expert Opin Investig Drugs, 12, pp. 1297-1312, (2003)
[5]
Mitchison D.A., The diagnosis and therapy of tuberculosis during the past 100 years, Am J Respir Crit Care Med, 171, pp. 699-706, (2005)
[6]
Guernsey B.G., Alexander M.R., Tuberculosis: Review of treatment failure, relapse and drug resistance, Am J Hosp Pharm, 35, pp. 690-698, (1978)
[7]
Neralla S., Glassroth J., Mycobacterium tuberculosis: The treatment of active disease, Semin Respir Infect, 18, pp. 392-406, (2003)
[8]
Benedetti S.M., Efthymiopoulos C., Sassella D., Et al., Autoinduction of rifabutin metabolism in man, Xenobiotica, 20, pp. 1113-1119, (1990)
[9]
Benedetti S.M., Dostert P., Induction and autoinduction properties of rifamycin derivatives: A review of animal and human studies, Environ Health Perspect, 102, pp. 101-105, (1994)
[10]
Loos U., Musch E., Jensen J.C., Et al., Pharmacokinetics of oral and intravenous rifampicin during chronic administration, Klin Wochenschr, 63, pp. 1205-1211, (1985)